The offices of the Port Gantry Register had become a war room. Maps and charts were pinned to the walls alongside Trina's existing corkboard of clippings, and the desks had been pushed together to form a long table covered with documents, photographs, and half-empty coffee cups. The air was thick with cigarette smoke and the particular electricity of a story that was still breaking, still evolving, still gathering force like a storm coming in from the sea.
Hale sat at the center of the long table, Cora Morrow's analysis of the consent forms spread out before him. She had worked through the night and delivered the brief that morning, a dense thirty-page document that dissected the forms with surgical precision. Every sentence, every clause, every choice of wording had been examined and found wanting. The forms were not designed to inform, she concluded. They were designed to create a legal shield, a paper barrier between Ravenwood and the consequences of its decisions.
"This is damning," Trina said, reading over his shoulder. "She's basically saying the consent forms constitute fraud."
"She's saying more than that. She's saying the forms were deliberately structured to deceive. That's not just fraud. That's criminal intent." Hale set down the brief. "Where is she now?"
"At her apartment. She's been working all night. I told her to get some sleep."
"Good. She's going to need it." Hale pulled out his notebook and reviewed the list of witnesses they had assembled. Latham Pryor, the recruiter who would testify that he was instructed not to inform patients about the cardiac risks. Gretchen Foss, the nurse who would testify that she was ordered to double-dose patients who showed side effects. Anton Raskin, the pharmacologist who would testify that the company knew the forty-milligram dose was lethal before the program launched. Marlene Draper, the former regional medical director who would testify that the entire program was designed to bury evidence of the drug's dangers. And now Cora Morrow, the paralegal who would testify that the consent forms were legally fraudulent.
Five witnesses. Five pieces of the machine, each one essential to understanding how it worked.
"It's not enough," Hale said quietly.
Trina looked up from the brief. "What do you mean, it's not enough? Five witnesses, internal documents, raw clinical data, a recorded confession—what else do you need?"
"We need someone who can trace the liability. All of our witnesses describe the machine from the inside. They describe what happened and how it happened. But they don't describe who ultimately profited from it. Ravenwood is a publicly traded company. The decisions that created the Exaltrex program weren't just medical decisions. They were financial decisions. Someone at the top made a calculation that the profits from the program would outweigh the costs. We need to find that calculation."
"How do we do that?"
Hale stood up and walked to the window. Outside, the Port Gantry shipyards were visible in the distance, the cranes swinging slowly against a sky that was clearing after days of rain. Somewhere beyond those cranes, beyond the harbor and the gray water, was the financial district of Meridian City, where Ravenwood's stock was traded and where the people who owned the company counted their returns.
"Securities fraud," he said. "If Ravenwood made false statements about Exaltrex's safety in their regulatory filings, and if investors bought stock based on those false statements, that's securities fraud. It's a separate crime from the patient deaths, but it's connected. The same lies that killed Edith Morrow and Walter Kemp were also told to investors."
Trina set down her coffee. "You're talking about a shareholder lawsuit."
"I'm talking about a criminal referral to the Union States Securities and Exchange Commission. But to make that referral, we need a shareholder. Someone who bought Ravenwood stock during the period when the company was making false statements about Exaltrex. Someone who has standing to demand an investigation."
"That's a very specific kind of person."
"I know." Hale turned from the window. "That's why I need you to find one."
The search for a Ravenwood shareholder took Trina two days. She worked the phones with the same intensity she had brought to the original investigation, calling pension fund managers and investment advisers and anyone who might have held Ravenwood stock during the relevant period. Most of them hung up on her. Some of them listened and declined to get involved. One of them, a fund manager at a small union pension in Port Gantry, said he would think about it and then called back an hour later to say his board had voted against participation.
"Nobody wants to touch this," Trina said on the second afternoon, her voice hoarse from hours of calls. "They're afraid of Ravenwood's lawyers. They're afraid of being sued. They're afraid of being dragged into a scandal."
"Keep trying. There has to be someone."
There was someone. His name was Isaac Voss, and he managed the pension fund for the United Longshoremen of Port Gantry, the same union that Trina's father had belonged to for thirty years. Voss was a cautious man in his late fifties, with the weathered face and broad shoulders of someone who had worked on the docks before moving into the union's administrative offices. He wore a jacket that was too heavy for the weather and carried a briefcase that had been repaired with electrical tape.
"I got your message," he said, sitting down across from Hale in the Register's conference room. "You want someone who held Ravenwood stock during the Exaltrex trial period. Our fund held a significant position. We bought shares in the company in March of last year, after their quarterly filing showed strong revenue growth from the pain management division. We sold in October, after rumors started circulating about problems with the compassionate use program. We took a loss of about forty thousand dollars."
"Forty thousand is significant," Hale said.
"For a union pension fund, it is. But that's not why I'm here." Voss opened his repaired briefcase and pulled out a folder. "My father died three years ago in a nursing home in Osric. Greenfield Manor. I didn't think much about it at the time. He was old. He had chronic pain. The death certificate said congestive heart failure. But after I read your story in the Register, I pulled his medical records." He slid the folder across the table. "He was in the Exaltrex program. He was on the forty-milligram dose. He died six weeks after starting the medication."
Hale opened the folder. Inside were copies of medical records from Greenfield Manor, medication administration logs showing Exaltrex forty milligrams, and a death certificate signed by Dr. Leland Orvis. The name on the certificate was Martin Voss. He had died fourteen months ago.
"I'm sorry," Hale said.
"Don't be sorry. Be angry. I am." Voss leaned forward, his heavy hands folded on the table. "I want to help you. Not just because of the forty thousand dollars. Because my father was a good man who worked on the docks for forty years and deserved better than to die as a data point in a corporate profit calculation. If there's a way to hold these people accountable, I want to be part of it."
Hale looked at Trina, who was standing by the door. She nodded once.
"Mr. Voss," Hale said, "if you're willing to serve as a lead plaintiff, we can file a securities fraud action against Ravenwood. The complaint would allege that the company made false and misleading statements about Exaltrex's safety in their quarterly filings, and that shareholders who bought stock based on those statements were defrauded. But I need to warn you: Ravenwood will fight this. They'll try to discredit you. They'll dig into your past. They'll make your life difficult."
"I've been a longshoreman for thirty-five years. I've been through strikes and lockouts and two attempts by the shipping companies to break the union. I'm not afraid of a pharmaceutical company." Voss stood up. "Tell me what you need."
Hale spent the next hour explaining the legal framework. The securities fraud action would be filed in federal district court, alleging violations of the Union States Securities Act. The core legal theory was straightforward: Ravenwood had made false statements about Exaltrex's safety in their regulatory filings, those statements had artificially inflated the company's stock price, and shareholders who bought during the period of inflation had been damaged when the truth emerged and the stock price fell.
But the legal theory also contained a challenge. Under the Securities Act, a plaintiff had to prove that their specific shares were purchased under the registration statement that contained the false statements. This was called the tracing requirement, and it was a notorious hurdle in securities litigation. Shares were fungible. Once they entered the market, it was nearly impossible to trace a specific purchase to a specific document.
"The tracing requirement," Voss said when Hale explained the problem. "How do we get around it?"
"We don't get around it. We meet it." Hale pulled out a copy of Ravenwood's quarterly filing from the previous March, the document that had convinced Voss's fund to buy the stock. "The false statements about Exaltrex's safety were in this filing. The fund bought shares in the month after this filing was issued. If we can trace the fund's purchase to the shares that were registered under this specific filing, we meet the requirement."
"How do we do that?"
"We need a forensic accountant. Someone who can analyze the trading records and the corporate issuance records and map the flow of shares. It's complicated, but it's possible."
"That's expensive," Voss said. "The union can contribute some money, but not enough for a forensic accountant and a securities lawsuit."
Hale had anticipated this. "There's a woman named Ida Cross. She's a public defender in Port Gantry. She's not a securities lawyer, but she knows the criminal side of this case. I think she can help us find a law firm that will take the case on contingency. If we win, the lawyers get paid from the judgment. If we lose, they get nothing."
"You think we can win?"
Hale looked at the folder of Martin Voss's medical records, at the death certificate signed by Dr. Leland Orvis, at the medication logs showing forty milligrams of Exaltrex. He thought about Edith Morrow's frozen eyes and Walter Kemp's blood on the linoleum. He thought about the internal Ravenwood memo that described the deaths as an acceptable cost.
"Yes," he said. "I think we can win."
Ida Cross arrived at the Register office that evening, her briefcase bulging with files and her expression carrying the particular exhaustion of someone who had been working on too many cases for too little money. She listened to Hale's explanation of the securities fraud theory while drinking coffee that Trina had brewed fresh.
"The tracing requirement is the key," she said when he finished. "If you can't trace the shares, you don't have standing. Without standing, the case is dismissed before discovery even begins."
"I know. That's why we need a forensic accountant."
"I know a firm. Marcotte and Ellison, in Meridian City. They specialize in securities litigation. They're expensive, but they've won some big cases. I can call them." She paused. "But there's another way to approach this. The criminal case is moving faster than I expected. The Union States Attorney's office called me this morning. They're opening a formal investigation into Ravenwood. The FDOA hearing is still on for next week, but the prosecutor wants to interview witnesses before then."
"Who are they interviewing?"
"Raskin first. Then Foss. Then Pryor. They want to lock in testimony before the hearing, so the witnesses can't change their stories later." She set down her coffee. "The prosecutor is a woman named Elaine Morse. She's the chief of the corporate fraud division. She has a reputation for being thorough and relentless. If she takes the case, Ravenwood will be facing criminal charges, not just regulatory fines."
"That's good."
"It's very good. But it also means you need to be careful. The more witnesses you talk to, the more the defense can argue that you coached them or influenced their testimony. Let the prosecutor do her job. You've done yours."
Hale nodded, but his mind was already moving ahead. The criminal investigation was essential, but it was also slow. The securities fraud case was a separate track, one that could pressure Ravenwood from a different direction. Together, they might be enough to break the machine entirely.
"There's one more thing," Ida said. "I pulled the incorporation records for Kernow Clinical Services. The contractor that employed Latham Pryor. It's a shell within a shell. Kernow is owned by a holding company called Aspen Medical Partners, which is owned by another holding company called Draven Holdings LLC."
"Draven Holdings," Hale said. "Marcus Draven?"
"Marcus Draven is the registered agent for Draven Holdings. The company was incorporated four years ago, six months before the Exaltrex compassionate use program launched. It's been receiving payments from Ravenwood ever since, routed through Kernow and Aspen. The payments total over two million dollars."
"So Marcus Draven wasn't just designing the program. He was personally profiting from it."
"It looks that way. The payments were for 'consulting services,' but there's no record of what those services were. If the money was being used to fund the patient recruitment program, and if Draven knew the program was killing patients, that's not just securities fraud. That's criminal fraud, possibly racketeering."
Hale stood up, the exhaustion of the past week momentarily forgotten. "Can you prove the connection?"
"I can prove the corporate structure. I can prove the payments. What I can't prove is what Marcus Draven knew and when he knew it. That's where the witnesses come in." She opened her briefcase and pulled out a document. "This is a subpoena request I'm filing tomorrow. It demands all financial records related to Draven Holdings, Kernow Clinical Services, and Aspen Medical Partners. If the judge approves it, we'll have access to bank statements, wire transfers, and tax filings. We'll be able to trace every dollar."
"That could take weeks."
"It could. But the subpoena is public record. The moment we file it, Ravenwood's lawyers will know what we're looking for. That alone might push them toward a settlement."
"A settlement isn't enough. We need admissions. We need accountability."
"Admissions and accountability come from criminal trials. Settlements come from civil suits. If we're smart, we'll pursue both." Ida closed her briefcase. "I'm meeting with the prosecutor tomorrow. I'll brief her on the Draven Holdings connection. In the meantime, focus on the securities case. The more pressure we apply from different directions, the harder it will be for Ravenwood to keep the machine intact."
She left, and Hale stood alone in the conference room, the documents spread out before him like a map of a country he was only beginning to understand. The machine had layers he had not anticipated. Marcus Draven, the vice president who had designed the program, had also been siphoning money through a chain of shell companies, profiting personally from the deaths of patients he had never met. The calculation in the internal memo—the acceptable cost—was not just a corporate abstraction. It was a personal revenue stream.
The telephone rang. It was Trina, calling from the newsroom.
"Isaac Voss called," she said. "He found another shareholder who wants to join the suit. A retired schoolteacher from Port Gantry who invested her savings in Ravenwood stock. She lost about twelve thousand dollars. She says she wants to help."
"That's good. We need as many plaintiffs as we can get."
"There's something else. Marlene Draper called the office. She says she needs to meet with you. She says she has something you need to see."
"Did she say what?"
"No. But she said it was urgent. She said to meet her at the chapel at Silver Pines, same as before." Trina paused. "Dominic, she's testified already. Her affidavit is filed. What more could she have to give you?"
Hale looked out the window at the darkening sky. The shipyard cranes were silhouettes against the gray, and the first lights of the harbor were beginning to flicker on.
"I don't know," he said. "But I'm going to find out."
No comments yet. Be the first to comment!